Pharmaceutical internal investigations in a post-pandemic world

The Chief of the Health Care Fraud Unit at the United States Attorney's Office, District of New Jersey, in-house counsel from Novartis and law firm partners address concerns specific to the pharmaceutical and medical device industries

You are invited to join us for a special webinar co-hosted by Compliance and Ethics Section of the National Hispanic Bar Association, the New Jersey Hispanic Bar Association, Norton Rose Fulbright and Friedman Kaplan featuring a high-level official from the Department of Justice and experienced in-house compliance and regulatory counsel.

The life sciences and healthcare sector is facing increased scrutiny by regulators. The government recognizes COVID-19 has disrupted everyone's lives and businesses and that this disruption has increased the possibility for misconduct and deviations from compliant business practices. They remain vigilant to appropriate enforcement of those who cut corners or exploit this situation.

The limitations on travel and in-person meetings has changed considerably the process of investigations. Social distancing and zoom interviews are now becoming the norm. This webinar will cover how to conduct investigations in this new reality and provide real world guidance on what the government expects a company to do.

Our conversation will explore perspectives from one of the key government enforcers, industry participants and counsel who are helping their clients navigate this new landscape.

Topics include:

• How to conduct an internal investigation remotely.
• Understanding what the government is most concerned with.
• What boards want and expect from their internal and external counsel.
• Familiarizing yourself with solutions that in-house teams have implemented.

Moderator

• Carlos F. Ortiz, Partner, Norton Rose Fulbright US LLP

Panel

• Lee Cortes, Chief, Health Care Fraud Unit at United States Attorney's Office, District of New Jersey
  • Lee's broader group heads the US Corona Virus Taskforce on Fraud.
• Adam Subervi, Director, Compliance, Investigations, Litigation, Product Promotion, Novartis
• Mayling C. Blanco, Partner, Norton Rose Fulbright US LLP
• Ricardo Solano, Partner, Friedman Kaplan